Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM196LK)

• Drug Name: MI-219 Drug Info
• Synonyms: CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Triple negative breast cancer	2C60-2C65	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 24877503
  TTD Drug ID: DM196LK

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ubiquitin-protein ligase E3 Mdm2 (MDM2)	TT08GJW	MDM2_HUMAN	Inhibitor	[1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Ubiquitin-protein ligase E3 Mdm2 (MDM2)	DTT	MDM2	5.162	4.909	4.174	2.907

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Triple negative breast cancer
• ICD Disease Classification: 2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Ubiquitin-protein ligase E3 Mdm2 (MDM2)	DTT	MDM2	1.19E-04	0.05	0.16

References

• [1] MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.